» Articles » PMID: 31129256

Intrinsic Relative Potency of a Series of Pyrrolizidine Alkaloids Characterized by Rate and Extent of Metabolism

Overview
Date 2019 May 27
PMID 31129256
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

1,2-Unsaturated pyrrolizidine alkaloids (PAs) are sometimes present in foods or herbal supplements/medicines as impurities and pose potential concerns for liver genotoxicity/carcinogenicity. PAs display a strong structure toxicity relationship, however, current regulatory approaches to risk assessment take the precautionary approach of assuming all PAs display the same potency as the most toxic congeners lasiocarpine (LAS) and riddelliine (RID). Here we explore the relative potencies of a series of structurally diverse PAs by measuring DNA adduct formation in vitro in a rat sandwich culture hepatocyte (SCH) cell system. The adducts generated are consistent with those identified in vivo as biomarkers of PA exposure and potential liver-tumor formation. DNA reactive PAs require metabolic activation to form intermediates that bind DNA, therefore, adduct formation is a direct reflection of reactive metabolite formation. Since the area under the concentration versus time curve (AUC) for the depletion of parent PA from the extracellular media is a measure of PA exposure, the ratio of adducts/AUC provides a measure of hepatocyte exposure to DNA-binding metabolites corresponding to an intrinsic potency for DNA adduct formation. Intrinsic potencies relative to potencies for LAS compare well with existing relative potency data further affirming that PA toxicity varies considerably with chemical structure.

Citing Articles

OCT1-dependent uptake of structurally diverse pyrrolizidine alkaloids in human liver cells is crucial for their genotoxic and cytotoxic effects.

Haas M, Ackermann G, Kupper J, Glatt H, Schrenk D, Fahrer J Arch Toxicol. 2023; 97(12):3259-3271.

PMID: 37676300 PMC: 10567918. DOI: 10.1007/s00204-023-03591-4.


Potency ranking of pyrrolizidine alkaloids in metabolically competent human liver cancer cells and primary human hepatocytes using a genotoxicity test battery.

Haas M, Wirachowski K, Thibol L, Kupper J, Schrenk D, Fahrer J Arch Toxicol. 2023; 97(5):1413-1428.

PMID: 36928417 PMC: 10110667. DOI: 10.1007/s00204-023-03482-8.


The Role of Kinetics as Key Determinant in Toxicity of Pyrrolizidine Alkaloids and Their N-Oxides.

Widjaja F, Alhejji Y, Rietjens I Planta Med. 2021; 88(2):130-143.

PMID: 34741297 PMC: 8807025. DOI: 10.1055/a-1582-9794.


Physiologically based kinetic modelling predicts the in vivo relative potency of riddelliine N-oxide compared to riddelliine in rat to be dose dependent.

Widjaja F, Wesseling S, Rietjens I Arch Toxicol. 2021; 96(1):135-151.

PMID: 34669010 PMC: 8748370. DOI: 10.1007/s00204-021-03179-w.


Pyrrolizidine alkaloid-induced transcriptomic changes in rat lungs in a 28-day subacute feeding study.

Buchmueller J, Sprenger H, Ebmeyer J, Rasinger J, Creutzenberg O, Schaudien D Arch Toxicol. 2021; 95(8):2785-2796.

PMID: 34185104 PMC: 8298252. DOI: 10.1007/s00204-021-03108-x.